Galenica (GALE) Q3 2026 TU earnings summary

Executive summary

• Jan–Sep 2026 net sales rose 5.7% to CHF 3,172.0m; growth excluding Labor Team was 2.7%.

• Pharmacy growth, home care and Diagnostics supported sales, while Q3 wholesale momentum was constrained by ERP-related product restrictions.

Financial highlights

• Products & Care net sales increased 10.9% to CHF 1,446.3m; Logistics & IT sales rose 2.7% to CHF 2,498.0m.

• Services & Production net sales grew 5.8% to CHF 93.6m; excluding Bichsel pharmaceutical production closure, growth was 10.5%.

Outlook and guidance

• FY 2026 sales growth guidance remains 5%–7%; adjusted EBIT growth guidance remains 6%–8%, excluding IAS 19, IFRS 16, IFRS 3 and one-off effects.

• Adjusted EBIT growth corresponds to 9%–11% excluding prior-year one-off items; Bichsel production-division closure costs were expected mainly in H1 2026 and excluded from adjusted EBIT.

• Q4 wholesale growth momentum is expected to improve following the successful ERP switchover.